Elsevier launches case report journal

Elsevier launched the International Journal of Surgery Case Reports (IJSCR), a new online journal dedicated exclusively to case reports.

The journal will serve as the companion to the International Journal of Surgery, and will be published eight times a year, in concert with its parent title. Submissions to the IJSC are peer-reviewed, although authors will have to pay almost $400 to publish their submissions, once accepted for publication.

Tom Reller, an Elsevier spokesperson, said the company has used the “author pays” model before, and IJSC has already received approximately 50 submissions for review. A few IJSC case reports have already been published in the company's Articles in Press category and included in the ScienceDirect online platform, and the first issue of the journal will publish “very shortly,” according to Reller. IJSC will be distributed as an online-only title.

Drug and device advertising is not currently present in the journal, although Reller said the implementation of ads “is certainly a possibility going forward.” Reller said the number of case reports per issue has yet to be determined, but that Elsevier expects the number to increase steadily over time.

“While infrequently cited for research purposes, case reports are popular and represent some of the oldest levels of evidence,” said David Rosin, editor-in-chief, and Riaz Agha, managing director and executive editor, in a joint statement.

Case reports include stories, anecdotes and patient-based learnings, and Elsevier hopes to raise their academic value by building a database of the reports, which “could be mined for interesting trends/patterns, disease modeling and for the purposes of surveillance, specially of rare diseases,” the statement said. Upon acceptance, case reports will also be posted on PubMed Central for accessibility across Elsevier's websites.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.